GEHC SEC Filings

GE HealthCare Technologies Inc. announced a significant leadership change with the appointment of William K. Grogan as its new Chief Financial Officer, effective September 14, 2026. Mr. Grogan brings extensive financial leadership experience, most recently serving as CFO of Xylem Inc. and previously as CFO of IDEX Corporation. This appointment marks a transition for the company, with current interim CFO George A. Newcomb returning to his role as Controller and Chief Accounting Officer. Mr. Grogan's compensation package reflects his experience and the incentives designed to attract and retain him, including a substantial base salary, annual bonus targets, and significant long-term equity awards. These awards are structured to align his interests with shareholders, with performance-based and time-based vesting components. The company also provided a cash sign-on payment and an equity award to compensate for forfeited compensation at his previous employer. Investors should monitor the integration of Mr. Grogan into the executive team and his impact on the company's financial strategy and performance.

GE HealthCare Technologies Inc. (GEHC) filed an 8-K on July 29, 2026, to announce its second quarter 2026 financial results. This filing primarily serves to furnish the accompanying press release, which details the company's performance for the period. Investors should refer to the press release (Exhibit 99) for specific financial figures, operational updates, and management's commentary on the quarter's results. The 8-K itself does not contain the detailed financial results but rather directs stakeholders to the furnished press release. This is a standard procedure for reporting quarterly earnings, allowing for timely dissemination of information. Key takeaways will be found within the press release, which typically includes metrics such as revenue, earnings per share (EPS), profit margins, segment performance, and forward-looking guidance. Investors should pay close attention to how GEHC performed against analyst expectations, the growth drivers within its key business segments (e.g., Imaging, Ultrasound, Pharmaceutical Diagnostics, and Edison X), and any commentary regarding macroeconomic factors or strategic initiatives that may impact future performance. The company's commentary on its strategic priorities and its ability to execute will be crucial for assessing long-term value.

GE HealthCare Technologies Inc. (GEHC) has filed an 8-K to disclose a strategic reorganization of its business segments, effective Q2 2026. The company has combined its Imaging and Advanced Visualization Solutions businesses into a new 'Advanced Imaging Solutions' (AIS) segment. This move is intended to enhance execution, accelerate innovation, and improve operational efficiencies. Following this change, GE HealthCare will now report under three distinct segments: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS). This new structure aligns with how the Chief Operating Decision Maker assesses performance and allocates resources. The AIS segment will encompass a broad range of diagnostic, interventional, and digital imaging technologies. Key product lines within AIS include Computed Tomography (CT), Magnetic Resonance (MR), Molecular Imaging (MI), solutions for Enterprise Imaging, Women's Health products (X-ray and Ultrasound), and general X-ray systems. The segment also includes offerings for CardioVascular and Interventional Solutions, as well as Surgical Innovations, and Comprehensive Care Ultrasound. The recast historical financial information reflecting this new segment structure is provided as an exhibit to aid investor comparability.

GE HealthCare Technologies Inc. reported solid revenue growth in the second quarter of 2026, with total revenues increasing by 5.7% year-over-year to $5.3 billion, driven by strong performance in its Advanced Imaging Solutions (AIS) and Pharmaceutical Diagnostics (PDx) segments. The company also benefited from the acquisition of Intelerad, which was integrated into the AIS segment. Net income attributable to GE HealthCare increased by 15.5% to $561 million, reflecting improved operational efficiencies and the positive impact of tariff refunds. Despite global macroeconomic uncertainties and supply chain challenges, GE HealthCare demonstrated resilience. The company successfully navigated the impact of tariffs through strategic pricing and the benefit of tariff refunds, which significantly boosted gross profit. However, the Patient Care Solutions (PCS) segment experienced a decline in revenue due to operational and fulfillment challenges. Looking ahead, the company remains focused on driving innovation and integrating strategic acquisitions while managing inflationary pressures and geopolitical risks.

GE HealthCare Technologies Inc. (GEHC) has filed an 8-K report disclosing preliminary unaudited financial results for the second quarter of 2026, which were also announced via a press release furnished as Exhibit 99. While specific figures for revenue and EPS are not detailed within the 8-K text itself, the furnishing of this preliminary data suggests the company is providing early guidance to the market. Investors should closely review the accompanying press release for the actual Q2 2026 performance metrics. Furthermore, the filing announces a significant leadership change: Chief Financial Officer James K. (Jay) Saccaro will be resigning on August 14, 2026, to pursue opportunities outside the medical technology sector. George Newcomb, currently Controller and Chief Accounting Officer, has been appointed interim CFO, effective August 14, 2026. Mr. Newcomb brings extensive finance experience from GE and GE Capital. The company has initiated a search for a permanent CFO. Investors should monitor the transition and the search process for a new CFO.

GE HealthCare Technologies Inc. (GEHC) filed an 8-K on May 11, 2026, detailing the results of its annual meeting of stockholders held on May 7, 2026. The filing confirms the election of all eight director nominees for one-year terms, with overwhelming support for most, including CEO Peter J. Arduini and H. Lawrence Culp, Jr. The advisory vote on executive compensation was also approved, though with a notable number of 'against' votes, suggesting potential investor concerns that warrant further attention from management. Additionally, the appointment of Deloitte & Touche LLP as the independent auditor for fiscal year 2026 was overwhelmingly ratified. Key leadership appointments were also announced effective May 7, 2026. Rodney F. Hochman has been appointed as the Board's independent lead director, and Anne T. Madden has been appointed as the chairperson of the Nominating and Governance Committee. These appointments signal continued focus on board oversight and governance practices. Investors should monitor the company's responsiveness to the executive compensation feedback received in the advisory vote.

GE HealthCare Technologies Inc. reported a decrease in net income attributable to GE HealthCare for the first quarter of 2026, down to $389 million from $564 million in the prior year period, primarily impacted by a significant increase in cost of products and services, alongside increased operating expenses. Total revenues saw a 7.4% increase to $5.13 billion, driven by growth in the PDx, Imaging, and AVS segments, with organic revenue growing 2.9%. The company completed a significant acquisition of Intelerad for approximately $2.3 billion, which contributed to a substantial increase in cash used for investing activities and a rise in goodwill. The company's operating income declined by 18.2% to $515 million, and the operating margin compressed by 310 basis points. This compression was largely attributed to higher cost of goods sold, impacted by cost inflation and incremental tariffs, as well as increased selling, general, and administrative expenses related to acquisitions. Despite these pressures, the company generated $290 million in cash from operating activities and $112 million in free cash flow, though this was impacted by the significant acquisition spend. The company also announced a strategic reorganization of its segments, combining Imaging and AVS into a new Advanced Imaging Solutions (AIS) segment starting in the second quarter of 2026.

GE HealthCare Technologies Inc. (GEHC) has filed an 8-K report on April 29, 2026, to announce its first quarter 2026 financial results via a press release furnished as Exhibit 99. While the specific financial details are within the press release, this filing serves as the official notification to the market regarding the company's performance during the first three months of 2026. Investors should refer to the press release for quantitative data such as revenue, earnings per share, and any segment-specific performance, as well as qualitative commentary from management on operational trends and future outlook. It is important for investors to note that the information provided in this 8-K, specifically the press release, is furnished and not deemed "filed" under Section 18 of the Securities Exchange Act of 1934. This means it is not subject to the same liabilities as formally filed information. However, it is still a critical source for understanding the company's reported financial condition and results of operations for the period. The filing also includes the standard XBRL cover page.

GE HealthCare Technologies Inc. announced a change to its Board of Directors via an 8-K filing on March 17, 2026. The company appointed Kevin A. Lobo as a new director and a member of the Talent, Culture, and Compensation Committee, effective March 13, 2026. Mr. Lobo's appointment is not the result of any disagreements or arrangements with other parties and will not trigger any reportable transactions under SEC regulations. Investors should note that Mr. Lobo will receive standard compensation for non-employee directors. Additionally, the filing disclosed that Risa Lavizzo-Mourey and Tomislav Mihaljevic will not seek re-election at the upcoming 2026 Annual Meeting of Stockholders. Their decisions are attributed to other commitments and not to any disputes with the company. These board changes, particularly the addition of Mr. Lobo, could signal a focus on executive oversight and compensation strategy.

GE HealthCare Technologies Inc. (GEHC) has filed an 8-K report detailing the execution of a new 364-day senior unsecured revolving credit agreement, effective February 26, 2026. This new agreement, which provides for a $0.5 billion facility, replaces a similar agreement from March 2025 that was terminated concurrently without penalty. The primary purpose of this filing is to inform investors about the company's ongoing access to liquidity through this credit facility, which is crucial for maintaining operational flexibility and managing short-term financial needs. The new credit agreement offers a maturity date of February 25, 2027, and provides flexibility in borrowing denominations (USD, EUR, GBP) with interest rates tied to various benchmarks like SOFR, EURIBOR, and SONIA, plus an applicable margin based on debt ratings. Standard covenants and events of default are included, typical for such facilities. This refinancing demonstrates GE HealthCare's ability to secure essential credit lines and maintain financial robustness, which are important considerations for investors assessing the company's stability and financial management.

GE HealthCare Technologies Inc. (GEHC) has filed an 8-K report on February 4, 2026, to announce its fourth quarter and full fiscal year 2025 financial results. The primary driver of this filing is the release of a press statement, furnished as Exhibit 99, which details the company's performance for the period ending December 31, 2025. Investors should note that the information within this press release is furnished and not formally filed, meaning it's not subject to the same liabilities under Section 18 of the Exchange Act and will not be automatically incorporated into future SEC filings unless specifically referenced. While the specific financial metrics are contained within the furnished press release (Exhibit 99), the report signals a key update for stakeholders on GEHC's operational and financial standing. Investors are encouraged to review the press release directly for detailed figures, including revenue, profitability, segment performance, and any forward-looking guidance provided by the company. This filing serves as the official notification of these results, making the press release the central document for understanding GEHC's latest financial performance.

GE HealthCare Technologies Inc. reported a solid year of revenue growth, with total revenues increasing by 4.8% to $20.625 billion. This growth was primarily driven by strong performance in the Pharmaceutical Diagnostics (PDx) segment, which saw a significant 15.6% revenue increase due to volume, pricing, and the acquisition of Nihon Medi-Physics Co., Ltd. (NMP). The Imaging and Advanced Visualization Solutions (AVS) segments also demonstrated growth, though they experienced some pressure in the China market. The Patient Care Solutions (PCS) segment saw a slight decline in revenue, mainly due to a decrease in Life Support Solutions. The company's operating income increased by 5.3% to $2.763 billion, reflecting improved gross profit despite increased costs for products and services driven by inflation and tariffs. Total operating expenses decreased, mainly due to reduced Spin-Off and separation costs, and a decrease in R&D spending as certain programs achieved milestones. The company also announced a significant agreement to acquire Intelerad for $2.3 billion, which is expected to enhance its imaging offerings and expand its reach into outpatient settings. Financially, the company ended the year with a strong cash position and managed its debt effectively.

GE HealthCare Technologies Inc. (GEHC) has announced significant financing activities through an 8-K filing on December 15, 2025. The company has secured a new three-year, $750 million senior unsecured term loan credit facility. This facility offers flexibility in interest rate options, allowing GEHC to choose between an alternate base rate or a SOFR rate, with applicable margins tied to its senior unsecured long-term debt ratings. In parallel, GEHC successfully issued $1.35 billion in senior unsecured notes, comprising $600 million of 4.150% Senior Notes due 2028 and $650 million of 4.950% Senior Notes due 2035. The combined proceeds from the term loan and these notes, along with existing cash, are earmarked to fund the previously announced acquisition of Intelerad Medical Systems. These financing actions indicate strategic moves to support growth initiatives and enhance the company's capital structure.

GE HealthCare Technologies Inc. (GEHC) announced on December 1, 2025, the successful pricing of a significant debt offering totaling $1.25 billion. The offering comprises $600 million in 4.150% Notes due December 15, 2028, and $650 million in 4.950% Notes due December 15, 2035. This move indicates the company's strategy to access capital markets, likely to fund ongoing operations, strategic initiatives, or refinance existing debt. Investors should note the coupon rates, which reflect current market interest rates and the company's credit profile at the time of issuance.

GE HealthCare Technologies Inc. reported a solid third quarter of 2025, demonstrating revenue growth and a significant increase in net income compared to the same period last year. Total revenues grew by 6% year-over-year, driven by robust performance across most segments, particularly Pharmaceutical Diagnostics (PDx) which saw a notable 20% increase fueled by the acquisition of Nihon Medi-Physics (NMP) and organic growth. The company also experienced strong growth in the Imaging and Advanced Visualization Solutions (AVS) segments. Despite some headwinds in the Patient Care Solutions (PCS) segment, the overall revenue trajectory is positive, indicating continued demand for GE HealthCare's diverse product and service offerings. Profitability saw a substantial improvement, with Net Income Attributable to GE HealthCare increasing by 18% for the nine-month period and by 3% for the quarter. While operating income saw a slight decrease for the quarter due to increased cost of goods sold and services impacted by inflation and tariffs, the nine-month operating income showed a healthy increase. The company's strategic focus on acquisitions, such as NMP, and ongoing investments in R&D and commercial teams, position it well for future growth. GE HealthCare's strong cash flow generation and healthy balance sheet, including increased cash reserves and managed debt levels, further underscore its financial stability.

GE HealthCare Technologies Inc. (GEHC) has filed an 8-K report on October 29, 2025, primarily to furnish a press release detailing its third quarter 2025 financial results. While the filing itself does not contain detailed financial statements, it serves as the official notification that the company has publicly shared its quarterly performance. Investors should refer to the furnished press release (Exhibit 99) for the specific figures and commentary regarding revenue, profitability, and any forward-looking statements made by management for the quarter ending September 30, 2025. This 8-K is a standard disclosure mechanism for earnings announcements. It's important to note that the information provided in the press release, as furnished under Item 2.02, is not considered "filed" for purposes of certain SEC regulations, meaning it does not automatically become part of GE HealthCare's formal SEC filings unless specifically incorporated by reference. Investors looking for a comprehensive understanding of GEHC's Q3 2025 performance, including operational metrics and strategic updates, will need to consult the press release itself.

GE HealthCare Technologies Inc. reported solid financial results for the six months ended June 30, 2025, with total revenues increasing by 3% to $9.78 billion. Net income attributable to GE HealthCare saw a significant jump of 31% to $1.05 billion, or $2.29 per diluted share. This growth was driven by robust performance across its segments, particularly the Pharmaceutical Diagnostics (PDx) segment, boosted by the full acquisition of Nihon Medi-Physics Co., Ltd. (NMP). The company also demonstrated improved operational efficiency, with operating income rising 12% year-over-year. While gross profit faced some pressure from cost inflation and tariffs, this was partially offset by a decrease in operating expenses, including lower R&D and SG&A costs. The company's liquidity remains strong, with $3.76 billion in cash, cash equivalents, and restricted cash, and access to $3.5 billion in revolving credit facilities, positioning it well to meet its financial obligations and invest in future growth.

GE HealthCare Technologies Inc. (GEHC) has filed an 8-K report on July 30, 2025, primarily to announce its second quarter 2025 financial results via a furnished press release. While the full details of the financial performance are contained within the press release (Exhibit 99), this filing itself serves as notification of the results. Investors should refer to the press release for comprehensive information regarding revenue, profitability, segment performance, and any forward-looking guidance provided by the company for the second quarter of 2025. The company also notes that this information is furnished, not filed, and therefore does not subject the company to Section 18 liabilities.

GE HealthCare Technologies Inc. (GEHC) has filed an 8-K report to announce the immediate resignation of Mr. Lloyd W. Howell, Jr. from its Board of Directors, effective July 23, 2025. The filing explicitly states that Mr. Howell's departure is not due to any disagreements concerning the Company's operations, policies, or practices, which suggests a voluntary or personal reason for his resignation. Investors should monitor any subsequent disclosures for potential insights into the Board's composition and strategic direction. While this is a significant change in Board leadership, the immediate nature and stated lack of disagreement indicate that day-to-day operations and strategic execution are not expected to be immediately impacted by this specific event. However, the departure of a director, particularly one who may have held specific expertise or influence, warrants investor attention. Further information regarding the reasons for his departure or any immediate plans to fill the vacancy may be of interest to shareholders.

GE HealthCare Technologies Inc. (GEHC) announced on June 9, 2025, the successful issuance of $1.5 billion in aggregate principal amount of senior unsecured notes. This offering comprises $650 million of 4.800% Senior Notes due January 15, 2031, and $850 million of 5.500% Senior Notes due June 15, 2035. The issuance was conducted under an effective shelf registration statement, indicating proactive capital management by the company. This debt issuance is a significant event for investors as it impacts the company's capital structure and financial leverage. The stated interest rates and maturity dates provide transparency into the cost of borrowing and the long-term debt obligations. Investors should consider how this new debt aligns with GEHC's overall financial strategy, potential use of proceeds, and its implications for future profitability and cash flow generation. The senior unsecured nature of the notes means they rank equally with other senior unsecured debt of the company.

GE HealthCare Technologies Inc. (GEHC) announced on June 4, 2025, the successful pricing of a significant debt offering, raising a total of $1.5 billion. The offering consists of two tranches: $650 million in 4.800% Notes due January 15, 2031, and $850 million in 5.500% Notes due June 15, 2035. This capital raise is being conducted under a previously filed registration statement and is expected to close around June 9, 2025. Investors should note that this debt issuance indicates the company's strategy to secure long-term financing. The specific use of proceeds is not detailed in this filing, but such offerings are typically made to fund operations, pursue strategic initiatives, refinance existing debt, or for general corporate purposes. The substantial amount raised suggests a significant strategic move by GE HealthCare.

GE HealthCare Technologies Inc. (GEHC) held its annual stockholders meeting on May 28, 2025, with the results of key votes detailed in this 8-K filing. The company's stockholders overwhelmingly re-elected all 10 nominated directors, indicating strong support for the current board leadership and strategic direction. Additionally, an advisory vote on executive compensation was approved, and the appointment of Deloitte & Touche LLP as the independent auditor for fiscal year 2025 received broad ratification. However, a notable outcome was the disapproval of a stockholder proposal seeking ratification of certain termination pay arrangements. This suggests potential investor concerns regarding specific compensation-related policies or structures that warrant further attention from management. Overall, the meeting affirmed confidence in the board and audit partner while highlighting an area for potential dialogue on executive pay-related provisions.

GE HealthCare Technologies Inc. (GEHC) reported a solid first quarter for 2025, with total revenues reaching $4.78 billion, a 3% increase year-over-year, and 4% on an organic basis. The company demonstrated strong profitability, with net income attributable to GE HealthCare rising 51% to $564 million, and diluted Earnings Per Share (EPS) increasing to $1.23 from $0.81 in the prior year. Key drivers of this performance include robust growth in the Pharmaceutical Diagnostics (PDx) segment and strong performance in the United States and Canada (USCAN). The company also benefited from a significant one-time gain from the remeasurement of its previously held 50% interest in Nihon Medi-Physics (NMP) as part of its acquisition. Despite some headwinds from unfavorable foreign currency impacts and ongoing challenges in the China market, GE HealthCare's operational execution and strategic acquisitions, like the full acquisition of NMP, are contributing positively to its financial results.

GE HealthCare Technologies Inc. (GEHC) has filed an 8-K report on April 30, 2025, detailing its first quarter 2025 financial results via an accompanying press release (Exhibit 99). While the specific financial performance details are within the press release, the report also announces a significant strategic move: the authorization of a new share repurchase program. The Board of Directors has approved a program allowing GE HealthCare to repurchase up to $1.0 billion of its common stock. This move signals management's confidence in the company's valuation and its commitment to returning capital to shareholders. The program's indefinite duration suggests a flexible approach to capital allocation, potentially allowing GEHC to take advantage of market opportunities over time.

GE HealthCare Technologies Inc. (GEHC) announced on March 31, 2025, the successful execution of two new senior unsecured revolving credit facilities with JPMorgan Chase Bank, N.A., totaling $3.5 billion in aggregate committed amount. These new facilities replace and update prior credit agreements, providing enhanced liquidity and potentially more favorable terms. The primary $3.0 billion credit facility matures in March 2030, offering long-term financial flexibility, while a new $0.5 billion 364-day facility replaces a previous $1.0 billion facility and matures in March 2026. This strategic refinancing demonstrates GEHC's proactive approach to managing its capital structure and ensuring robust access to funding. The new agreements include standard covenants and events of default, typical for corporate credit facilities, and the interest rates will be determined by market benchmarks plus a margin tied to the company's credit ratings. Investors should view this as a positive development, signaling financial stability and continued operational support through established banking relationships.

GE HealthCare Technologies Inc. (GEHC) reported robust performance for the fiscal year 2024, demonstrating resilience and strategic execution in a dynamic global healthcare market. Total revenues reached $19.67 billion, a slight increase of 1% year-over-year, driven primarily by growth in services and a strong performance in the Pharmaceutical Diagnostics (PDx) segment. Despite a 1% dip in the Imaging segment, the company saw growth in Advanced Visualization Solutions (AVS) and Patient Care Solutions (PCS), albeit modest. The PDx segment was a standout, with a 9% revenue increase, fueled by volume, pricing, and new product introductions. Geographically, the company experienced a 5% revenue increase in the United States and Canada (USCAN), while EMEA remained flat. China, however, saw a significant 15% decline in revenues, attributed to the lingering effects of prior stimulus programs and an ongoing anti-corruption campaign impacting healthcare sector spending. The company's profitability also saw improvement, with operating income increasing by 8% and net income attributable to GE HealthCare rising by 27% to $1.99 billion. This was supported by improved gross profit margins, cost productivity initiatives, and a reduction in interest expenses. GEHC remains focused on innovation, particularly in AI and digital solutions, which are integrated across its product lines to enhance patient care and operational efficiency for healthcare providers.

GE HealthCare Technologies Inc. (GEHC) filed an 8-K on February 13, 2025, to announce its fourth quarter and full fiscal year 2024 financial results. The primary purpose of this filing is to furnish the accompanying press release, which contains the detailed financial performance and operational updates. Investors should refer to the press release (Exhibit 99) for specific metrics regarding revenue, profitability, segment performance, and any forward-looking guidance provided by the company. This report serves as a notification of the release of these results and does not represent new material information beyond what is contained in the furnished press release. The information is provided under Item 2.02 and is considered "furnished," not "filed," meaning it does not carry the same liability implications as a formally filed document under Section 18 of the Exchange Act. Investors are advised to review the press release for a comprehensive understanding of GE HealthCare's recent performance and outlook.

GE HealthCare Technologies Inc. (GEHC) has entered into a new 364-Day Revolving Credit Agreement totaling $1.0 billion, effective December 11, 2024. This facility replaces a similar agreement that matured on the same date and provides GEHC with continued access to unsecured revolving credit for general corporate purposes. The agreement allows for borrowings in U.S. Dollars and Euros and matures on December 10, 2025. The terms of the new credit facility include variable interest rates based on benchmark rates (Alternate Base Rate, Adjusted Term SOFR, or EURIBOR) plus an applicable margin determined by GEHC's senior unsecured long-term debt ratings. The company retains the flexibility to prepay borrowings and reduce commitments without penalty, subject to customary provisions. The agreement also includes standard covenants limiting indebtedness, liens, and leverage, which are consistent with GEHC's existing credit facilities, and customary events of default.

GE HealthCare Technologies Inc. (GEHC) filed an 8-K on November 21, 2024, primarily to furnish a press release related to its upcoming 2024 Investor Day. This filing does not contain new financial results or significant operational updates; rather, it serves as a notification and provides access to materials that will likely be discussed at the investor event. Investors should look to the Investor Day itself for detailed strategic discussions, financial outlook, and potentially new guidance from the company.

GE HealthCare Technologies Inc. (GEHC) announced the commencement and pricing of an underwritten offering of approximately 13.3 million shares of its common stock. Importantly, GE HealthCare itself will not be selling any shares and will not receive any proceeds from this offering. Instead, the shares are being offered by Morgan Stanley & Co. LLC, acting as a selling stockholder. Prior to this sale, GE Aerospace is expected to exchange these GEHC shares for indebtedness it holds with Morgan Stanley Bank, N.A. This transaction represents a debt-for-equity exchange involving GE Aerospace, with the resulting GEHC shares then being sold into the market by the designated selling stockholder. Investors should note that this offering primarily impacts the ownership structure of GEHC shares held by GE Aerospace and its affiliates, rather than directly raising capital for GE HealthCare.

GE HealthCare Technologies Inc. (GEHC) has filed an 8-K to disclose a change in its reportable business segments, effective July 1, 2024. The Image Guided Therapies (IGT) business, previously part of the Imaging segment, has been realigned to the Ultrasound segment, which has been renamed Advanced Visualization Solutions (AVS). This change aims to better align IGT with its clinical applications and enhance business and customer impact by providing integrated image guidance. The recast financial information for this new segment structure for fiscal years 2023 and 2022, and the first two interim periods of 2024, is provided to aid investor comparability.

GE HealthCare Technologies Inc. (GEHC) reported a solid third quarter for 2024, with total revenues reaching $4.86 billion, a 1% increase both on a reported and organic basis compared to the prior year. This growth was driven by a 2% increase in service revenues and a slight uptick in product sales, despite challenges in the China market due to an ongoing anti-corruption campaign and delayed stimulus program. Operating income saw a significant increase of 10% to $676 million, and net income attributable to GE HealthCare common stockholders rose by 25% to $470 million, reflecting strong cost productivity and favorable pricing. The company also demonstrated robust cash flow generation, with operating cash flow of $1.04 billion for the nine-month period. Financially, GEHC maintained a strong balance sheet with $3.57 billion in cash, cash equivalents, and restricted cash as of September 30, 2024. The company successfully issued $1 billion in senior unsecured notes, strengthening its liquidity position. Remaining Performance Obligations (RPO) stood at $14.56 billion, indicating a healthy future revenue pipeline, though slightly down 1% from the end of 2023. The company's strategic acquisitions, such as MIM Software, are being integrated, and management remains optimistic about long-term growth prospects, particularly in expanding healthcare access globally.

GE HealthCare Technologies Inc. (GEHC) announced its third quarter 2024 financial results on October 30, 2024, via a press release furnished with this 8-K filing. While the 8-K itself does not contain detailed financial figures, it serves as the official notification of the release of these results. Investors should refer to the press release (Exhibit 99) for comprehensive details on GE HealthCare's performance, including revenue, profitability, and any forward-looking guidance issued by the company. The filing clarifies that the information furnished under Item 2.02 is not considered 'filed' for certain legal purposes, emphasizing the importance of reviewing the actual press release for actionable financial data and analysis.

GE HealthCare Technologies Inc. (GEHC) announced on September 12, 2024, the commencement and pricing of an underwritten offering of 15,000,000 shares of its common stock at $86.00 per share. It is crucial for investors to note that GEHC itself is not selling any shares and will not receive any proceeds from this offering or an associated debt-for-equity exchange. The shares being offered are currently held by GE Aerospace, which is expected to exchange them for its own indebtedness held by Morgan Stanley Bank, N.A. and Morgan Stanley Senior Funding, Inc. prior to the closing of the offering. Following this debt-for-equity exchange, Morgan Stanley & Co. LLC, acting as the selling stockholder, intends to sell these GEHC shares to the underwriters. This transaction primarily facilitates the divestiture of GE Aerospace's stake in GEHC and a debt reduction for GE Aerospace, without direct capital infusion into GEHC. Investors should monitor the completion of this offering and the subsequent market performance of GEHC shares.

GE HealthCare Technologies Inc. (GEHC) has announced the issuance of $1 billion in aggregate principal amount of 4.800% Senior Notes due August 14, 2029. This offering was conducted under the company's effective shelf registration statement. The notes are senior unsecured obligations and rank equally with other existing senior unsecured indebtedness of GEHC. This move indicates GEHC's proactive approach to managing its capital structure and likely reflects a strategy to secure long-term funding at a specific interest rate. Investors should note that this issuance increases the company's outstanding debt, but it also provides a clear cost of capital for this portion of its financing. The proceeds from this issuance are not explicitly detailed in this filing, but typically such issuances are used for general corporate purposes, potential acquisitions, or refinancing existing debt.

GE HealthCare Technologies Inc. (GEHC) announced on August 7, 2024, the pricing of an underwritten offering of $1,000,000,000 aggregate principal amount of 4.800% Notes due August 14, 2029. This debt issuance, conducted under a previously filed Form S-3 registration statement, is expected to close around August 14, 2024, subject to standard closing conditions. The offering was managed by prominent underwriters including Goldman Sachs & Co. LLC, BofA Securities, Inc., and Morgan Stanley & Co. LLC. This debt financing suggests GEHC is actively managing its capital structure, potentially to fund strategic initiatives, ongoing operations, or refinance existing debt. Investors should monitor the company's subsequent filings for details on the use of proceeds from this offering and its impact on the company's leverage and financial flexibility. While the specific purpose is not detailed in this 8-K, such debt issuances are common for mature companies looking to optimize their capital mix.

GE HealthCare Technologies Inc. (GEHC) reported relatively flat total revenues of $4.84 billion for the three months ended June 30, 2024, a slight increase of 1% organically, compared to the prior year period. For the six-month period, total revenues remained flat at $9.49 billion. While product sales saw a slight decline, service revenues experienced growth, driven by pricing increases. Profitability showed a positive trend, with operating income increasing by 7% to $608 million for the quarter and by 2% to $1.15 billion for the six months. Net income attributable to GE HealthCare also saw an increase, reaching $428 million for the quarter and $802 million for the six months. The company reported strong performance in its Pharmaceutical Diagnostics (PDx) segment, which grew 12% in the quarter and 10% year-to-date, driven by volume, price, and new product introductions. Conversely, the China market continues to be a headwind, with revenues down 18% for the quarter, impacted by an ongoing anti-corruption campaign and delayed stimulus programs. Geographically, the United States and Canada (USCAN) region showed robust growth of 5% in the quarter, while EMEA was flat and the Rest of World grew 8%. The company has also made progress in its strategic acquisitions, including the acquisition of MIM Software Inc. in April 2024, which is expected to contribute to the Imaging segment. Cash flow from operations was $300 million for the six months, lower than the previous year, leading to a decrease in free cash flow, which management attributes to factors such as higher inventory levels and increased compensation and benefit payments.

GE HealthCare Technologies Inc. (GEHC) has filed an 8-K on July 31, 2024, primarily to announce its second quarter 2024 financial results via an accompanying press release (Exhibit 99). While the 8-K itself does not contain detailed financial figures, it directs investors to the press release for the comprehensive results. This filing signifies the company's adherence to disclosure requirements regarding significant corporate events, in this case, the release of quarterly earnings. Investors should refer to the furnished press release for specifics on revenue, profitability, segment performance, and any forward-looking guidance. This report is typical for companies announcing quarterly earnings and serves as a formal notification to the market. The key information for investors will be within the press release itself, which is expected to detail GEHC's operational and financial performance for the second quarter of 2024. Investors interested in GEHC's current financial standing and outlook should seek out this press release for a complete understanding of the reported results and any management commentary provided.

GE HealthCare Technologies Inc. (GEHC) filed an 8-K on May 23, 2024, detailing the results of its annual meeting of stockholders held on May 21, 2024. The report confirms the election of all 10 nominated directors, who will serve until the 2025 annual meeting. Additionally, stockholders provided advisory approval for the compensation of named executive officers and ratified the appointment of Deloitte & Touche LLP as the company's independent auditor for the fiscal year ending December 31, 2024. These voting outcomes indicate strong shareholder confidence in the current board of directors and the company's auditor. The overwhelming approval of executive compensation, though advisory, suggests alignment between management and investors on compensation structures. The ratification of the auditor is a routine but important step in corporate governance, ensuring independent oversight of financial reporting.

GE HealthCare Technologies Inc. (GEHC) filed an 8-K on April 30, 2024, primarily to furnish a press release detailing its first quarter 2024 financial results. While the 8-K itself does not contain detailed financial tables or analysis, it directs investors to the attached press release (Exhibit 99) for the company's performance update. Investors should review this press release for specific revenue, earnings, and segment performance data, as well as any forward-looking guidance provided by the company for the upcoming periods. It's important to note that the information in the press release is furnished, not filed, meaning it is not subject to the same liability provisions as other parts of the 8-K under Section 18 of the Exchange Act, but it remains a crucial source of current operational and financial information.

GE HealthCare Technologies Inc. reported total revenues of $4.65 billion for the first quarter of 2024, a slight decrease of 1% compared to the prior year period, which was largely flat on an organic basis. This modest top-line performance was driven by mixed segment results, with the Pharmaceutical Diagnostics (PDx) segment showing strong growth, while Imaging, Ultrasound, and Patient Care Solutions (PCS) experienced declines. Despite the slight revenue dip, the company demonstrated improved profitability metrics. Operating income saw a slight decrease, but Adjusted EBIT and Adjusted Net Income increased by 3% and 6% respectively, indicating effective cost management and operational efficiencies. Diluted Earnings Per Share (EPS) significantly improved to $0.81 from $0.41 in the prior year, largely due to the absence of a large deemed preferred stock dividend related to redeemable noncontrolling interests in the prior year. The company maintained a strong liquidity position with $2.56 billion in cash and cash equivalents and access to substantial credit facilities, positioning it to fund operations and strategic initiatives, including a recent acquisition in April 2024.

GE HealthCare Technologies Inc. (GEHC) announced the resignation of Jan Makela, Chief Executive Officer of its Imaging segment, effective July 8, 2024. Mr. Makela is departing to assume the CEO role at a private, non-competitive company. This leadership change within a key segment warrants investor attention, as the Imaging division is a significant contributor to GEHC's overall revenue and profitability. The company has indicated it will be evaluating both internal and external candidates to fill this critical position, suggesting a thorough search process is underway.

GE HealthCare Technologies Inc. (GEHC) announced on March 12, 2024, the commencement and pricing of an underwritten offering of 14,000,000 shares of its common stock. Importantly, GEHC itself is not selling any shares and will not receive any proceeds from this offering. Instead, the shares being sold originate from General Electric Company (GE). Prior to the sale, GE is expected to exchange these shares for its own indebtedness held by Morgan Stanley Bank, N.A. Subsequently, Morgan Stanley & Co. LLC, acting as the selling stockholder, will sell the shares to the underwriter. This transaction is part of GE's broader strategy to divest its stake in GEHC, and investors should note that the share price and the total amount raised will be determined by the market and the underwriter, not directly by GEHC. The company has also provided standard forward-looking statements related to the offering.

GE HealthCare Technologies Inc. (GEHC) announced on February 15, 2024, the commencement and pricing of an underwritten offering of 13 million shares of its common stock. The offering price is set at $82.25 per share. Importantly, GEHC itself is not selling any shares and will not receive any proceeds from this offering or an associated debt-for-equity exchange. Instead, General Electric Company (GE) will exchange its holdings of GEHC shares for indebtedness owed to Morgan Stanley. Morgan Stanley & Co. LLC, acting as the selling stockholder, will then sell these shares to underwriters. This transaction primarily impacts the ownership structure and liquidity of GEHC shares in the market, with a significant number of shares being sold by an affiliate of GE. Investors should note that the proceeds are not going to GEHC for its operational or strategic initiatives, but rather represent a divestiture by GE and a facilitated sale by Morgan Stanley. The company has also filed a registration statement (Form S-3) and is subject to standard market and closing conditions for the offering.

GE HealthCare Technologies Inc. (GEHC) has filed an 8-K report on February 6, 2024, to announce its fourth quarter and full fiscal year 2023 financial results. The core of this filing is the accompanying press release (Exhibit 99), which details the company's performance. Investors should note that the information furnished in this report, specifically regarding the financial results, is not considered "filed" for the purposes of Section 18 of the Exchange Act, meaning it doesn't carry the same legal liabilities as formally filed information. However, it serves as the primary source for understanding GEHC's recent financial standing and operational outcomes for the periods ending December 31, 2023. While the 8-K itself is brief, it directs investors to the press release for comprehensive financial data, including revenue, earnings, and potentially guidance for future periods. Investors will need to review Exhibit 99 to gain a full understanding of GEHC's profitability, growth drivers, and any significant financial events or strategic updates disclosed for the fourth quarter and the entirety of fiscal year 2023. This filing is a standard mechanism for publicly traded companies to disseminate timely financial information to the market.

GE HealthCare Technologies Inc. (GEHC) filed an 8-K on February 6, 2024, primarily to furnish its fourth quarter and full fiscal year 2023 financial results, as detailed in a press release included as an exhibit. This filing serves as an announcement of their performance, providing investors with key financial metrics and operational updates. While the 8-K itself is largely a notification of the press release, the underlying financial data contained within that release is critical for understanding the company's recent performance and future outlook. Investors should carefully review the press release (Exhibit 99) for specific details regarding revenue, profitability, segment performance, and any forward-looking guidance provided by GE HealthCare. This information is essential for assessing the company's trajectory, competitive positioning, and overall financial health following the reporting period. It's important to note that information furnished under Item 2.02 is not considered "filed" for purposes of Section 18 of the Exchange Act, meaning it doesn't carry the same legal implications as formally filed documents, but it remains a primary source for timely financial disclosures.

GE HealthCare Technologies Inc. (GEHC) has filed an 8-K report on February 6, 2024, primarily to furnish its fourth-quarter and full-year 2023 financial results, as detailed in an accompanying press release (Exhibit 99). While the 8-K itself doesn't contain the detailed financial data, it signals the official release of this information to the market. Investors should refer to the furnished press release for a comprehensive understanding of the company's performance, including revenue, profitability, and any forward-looking guidance provided for the upcoming periods. The filing also includes standard XBRL exhibits for data tagging. This report serves as the official notification of GEHC's latest financial performance. The key takeaway for investors is to access and analyze the press release for critical insights into GE HealthCare's operational and financial condition. This includes understanding the drivers behind their quarterly and annual results, assessing the company's strategic progress, and evaluating any management commentary regarding future outlook and potential challenges or opportunities. The furnishing of this information under Item 2.02 means it's for informational purposes and not officially 'filed' under certain securities regulations, a common practice for earnings releases.

GE HealthCare Technologies Inc. (GEHC) reported a 7% increase in total revenues for the fiscal year ended December 31, 2023, reaching $19.55 billion. This growth was driven by broad-based strength across its four key segments: Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment, the largest contributor, saw a 6% revenue increase, while PDx demonstrated robust 18% growth. Net income attributable to GE HealthCare decreased by 18% to $1.57 billion, primarily due to increased operating expenses related to its standalone company status and higher interest expenses following its separation from GE. Despite the net income dip, the company generated strong free cash flow of $1.72 billion, underscoring its operational efficiency and ability to manage cash. GE HealthCare continues to invest in research and development, with a focus on digital solutions and AI, positioning itself for future growth in the evolving healthcare landscape. Financially, the company ended the year with $2.50 billion in cash and cash equivalents. GEHC's total debt increased to $9.44 billion, largely due to financing activities related to its 2023 spin-off from GE. Management expressed confidence in the company's liquidity, believing existing cash, operating cash flow, and credit facilities will be sufficient to meet its needs for the next 12 months. The company also continues to navigate global economic and geopolitical uncertainties, as noted in its risk factors, but its diversified product portfolio and global reach provide a degree of resilience.

GE HealthCare Technologies Inc. (GEHC) announced the resignation of its Chief People Officer, Betty D. Larson, effective March 21, 2024. This change in a key executive position, particularly the head of human resources, is a notable event that investors should monitor. While the filing does not provide specific reasons for Ms. Larson's departure or details about her severance, such transitions can sometimes signal shifts in company strategy or culture. Investors will likely be keen to understand the succession plan for this critical role and the impact, if any, on employee morale, talent acquisition, and retention efforts.

GE HealthCare Technologies Inc. (GEHC) announced on December 15, 2023, the entry into a new $1.0 billion 364-day senior unsecured revolving credit facility. This new facility, dated December 13, 2023, was established concurrently with the termination of a previous, similar $1.0 billion 364-day facility that was set to mature in January 2024. The new credit agreement with Citibank, N.A. as administrative agent provides financial flexibility and is structured with provisions for various interest rate options (Alternate Base Rate, Adjusted Term SOFR, or EURIBOR) plus an applicable margin based on debt ratings. The company may also prepay borrowings and reduce commitments without penalty, subject to customary terms. This move suggests GEHC is proactively managing its short-term liquidity and debt structure. The termination of the old facility without penalty and the establishment of a new one of the same size and tenor indicates a seamless rollover of its short-term credit lines, likely to maintain robust access to capital and optimize borrowing costs. Investors should note the covenants are consistent with existing facilities, implying no significant changes in the company's financial obligations or risk profile related to this credit line.